Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 39

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 39
---

protect our technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative
research agreements, consulting agreements, or other similar agreements with our collaborators, advisors, employees and consultants prior
to beginning research or disclosing information. These agreements typically limit the rights of the third parties to use or disclose
our confidential information, such as trade secrets and intellectual property. Despite the contractual provisions employed when working
with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become
known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these
agreements. Given that our position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade
secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.
In addition, certain of our officers are also engaged by third parties, including our Chief Financial Officer, which provides his services
to us through a third-party service firm. See “Management—Engagement Agreements with Executive Officers” for additional
information.

Despite our efforts to protect
our trade secrets and knowhow, our competitors may discover our trade secrets, either through breach of these agreements, independent
development or publication of information including our trade secrets by third parties. A competitor’s discovery of our trade secrets
and knowhow would impair our competitive position and have an adverse impact on our business, financial condition, results of operations
and prospects.

<div align='center'>28</div>

Risks Related to Our Intellectual Property

If we are unable to obtain significant patent protection for our products, or if our patents and other intellectual property rights do not adequately protect our products, we may be unable to gain significant market share and be unable to operate our business profitably.

We will rely on patents,
trade secrets, copyrights, know-how, trademarks, license agreements and contractual provisions to establish our intellectual property
rights and protect our products. These legal means, however, afford only limited protection and may not completely protect our rights.

As of July 7, 2025,
our exclusively owned patent portfolio includes thirty-four (34) issued patents, of which eight (8) are U.S. patents and twenty-six (26)
are foreign patents, with eighteen (18) of the twenty-six (26) foreign patents being nationally validated in certain European extension/validation
states). We cannot assure you that our intellectual property position will not